CAT panel questions GSK counsel on by-object restrictions
A lawyer acting for GlaxoSmithKline today argued that the company’s patent settlements with two generic drugmakers cannot be painted as by-object restrictions of competition – but faced questions on his approach by members of the Competition Appeal Tribunal.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Subscribe now